Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its participation in the upcoming 2025 Sequire Investor Summit in San Juan, Puerto Rico.
The company's President and CEO, David J. Mazzo, PhD, will deliver a corporate overview presentation on Wednesday, January 22, 2025, at 10:00 a.m. Atlantic Standard Time. The summit is scheduled to take place from January 21-23, 2025.
Lisata Therapeutics (Nasdaq: LSTA), un'azienda farmaceutica in fase clinica specializzata nello sviluppo di terapie innovative per tumori solidi avanzati e altre malattie gravi, ha annunciato la sua partecipazione al prossimo 2025 Sequire Investor Summit a San Juan, Porto Rico.
Il presidente e CEO dell'azienda, David J. Mazzo, PhD, presenterà una panoramica aziendale mercoledì 22 gennaio 2025, alle 10:00 ora standard dell'Atlantico. Il summit si terrà dal 21 al 23 gennaio 2025.
Lisata Therapeutics (Nasdaq: LSTA), una empresa farmacéutica en fase clínica enfocada en desarrollar terapias innovadoras para tumores sólidos avanzados y otras enfermedades graves, ha anunciado su participación en el próximo 2025 Sequire Investor Summit en San Juan, Puerto Rico.
El presidente y CEO de la empresa, David J. Mazzo, PhD, realizará una presentación de la visión general de la empresa el miércoles 22 de enero de 2025, a las 10:00 a.m. hora estándar del Atlántico. La cumbre está programada para llevarse a cabo del 21 al 23 de enero de 2025.
리사타 테라퓨틱스 (Nasdaq: LSTA), 혁신적인 암 치료제 및 기타 중병 치료제를 개발하는 데 집중하는 임상 단계의 제약 회사가 2025 세퀴레 투자 서밋에 참석할 것임을 발표했습니다. 이 행사는 푸에르토리코의 산후안에서 열립니다.
회사의 회장 겸 CEO인 데이비드 J. 마조, PhD가 2025년 1월 22일 수요일 오전 10시 (대서양 표준시)에 기업 개요 발표를 진행할 예정입니다. 이번 서밋은 2025년 1월 21일부터 23일까지 진행될 예정입니다.
Lisata Therapeutics (Nasdaq: LSTA), une entreprise pharmaceutique en phase clinique axée sur le développement de thérapies innovantes pour les tumeurs solides avancées et d'autres maladies graves, a annoncé sa participation au prochain 2025 Sequire Investor Summit à San Juan, Porto Rico.
Le président et PDG de l'entreprise, David J. Mazzo, PhD, présentera un aperçu de l'entreprise le mercredi 22 janvier 2025, à 10h00, heure standard de l'Atlantique. Le sommet est prévu du 21 au 23 janvier 2025.
Lisata Therapeutics (Nasdaq: LSTA), ein in der klinischen Phase befindliches Pharmaunternehmen, das sich auf die Entwicklung innovativer Therapien für fortgeschrittene solide Tumoren und andere schwere Krankheiten konzentriert, hat seine Teilnahme am bevorstehenden 2025 Sequire Investor Summit in San Juan, Puerto Rico, bekannt gegeben.
Der Präsident und CEO des Unternehmens, David J. Mazzo, PhD, wird am Mittwoch, den 22. Januar 2025, um 10:00 Uhr Atlantic Standard Time eine Unternehmensübersicht präsentieren. Der Gipfel findet vom 21. bis 23. Januar 2025 statt.
- None.
- None.
BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming Sequire Investor Summit being held January 21-23, 2025 in San Juan, Puerto Rico.
Dr. Mazzo’s presentation is scheduled for Wednesday, January 22 at 10:00 a.m. Atlantic Standard Time. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/.
About SRAX
SRAX Inc. is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s internalizing RGD, or arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Lisata Therapeutics (LSTA) presenting at the 2025 Sequire Investor Summit?
What will be discussed at Lisata's (LSTA) Sequire Investor Summit presentation?
Where is the 2025 Sequire Investor Summit featuring Lisata (LSTA) being held?
What is Lisata Therapeutics' (LSTA) current business focus?
